| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ArriVent BioPharma, Inc.$33.69
+0.02 (+0.06%)
B 69Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.24 B
EPS
-3.53
P/E Ratio
-
Value Trade
21.17 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
37.62 M
Operating CF
-41.89 M
Total Assets
349.30 M
Total Liabilities
25.32 M
Equity
323.98 M
D/E Ratio
12,345
-4.84 %
Week
-14.74 %
1 Month
16.83 %
3 Month
34.46 %
6 Month
11.38 %
5 Year
11.38 %
All Time
Cash Data
Cash Position
326.38 M
Monthly Burn
13.96 M
Runway
21.6 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
436.62 K
52 Week Range
16.10 - 32.14
% held by Insiders
28.35 %
% held by Institutions
69.99 %
Enterprise Value
918.99 M
Total Shares
41.30 M
Short %
35.17 %
Float Shares
21.68 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ArriVent BioPharma, Inc.
91Total events
3Upcoming
20Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 3
Event history 88
Q3 2026
◆Trial InitiationARR-002Trial
Phase 1 trial initiation expected
ovarian and endometrial cancerssource ↗
Q3 2026
▲First Patient DosedARR-002Trial
First patient dosing expected
ovarian and endometrial cancerssource ↗
Q3 2026
◆Dose Finding UpdateARR-217Trial
Initiate Phase 1 dose optimization for ARR-217
gastrointestinal malignanciessource ↗
Jun 2026
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC
first-line EGFR exon 20 insertion mutant NSCLCsource ↗
May 7, 2026
Apr 21, 2026
◆Poster PresentationPresentation
Poster presentation on Exatecan Payload-Based ADCs with AQUALINK platform at AACR 2026
Apr 21, 2026
◆Poster PresentationFirmonertinibApprovedPresentation
Poster presentation on discovery and characterization of firmonertinib at AACR 2026
EGFR exon 20 insertion mutant non-small cell lung cancersource ↗
Apr 21, 2026
◆Oral PresentationARR-002Presentation
Oral presentation by Aarvik on ARR-002 at AACR Clinical Research Mini Symposium
ovarian and endometrial cancerssource ↗
Apr 20, 2026
◆Poster PresentationPresentation
Poster presentation of AV-P138-ADC (ARR-002) at AACR 2026
ovarian and endometrial cancerssource ↗
Drug Pipeline Intelligence
B69
Pipeline Score $7.7B
Pipeline ValueUndervalued
Valuation Signal10
Drugs Scored6.2x
rNPV / MCap Top 94%
Micro Cap (rank 56 of 911)
Percentile RankArriVent BioPharma, Inc. holds a solid B-grade pipeline (69/100), with $20.5B risk-adjusted pipeline value, led by Drug: Furmonertinib in Non-small Cell Lung Carcinoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug: Furmonertinib Small molecule | Non-small Cell Lung Carcinoma | Phase 3 | NCT04853342 | 79% | $5.4B | RECRUITING | 318 | STALLED | B (60) | Jan 1, 2030 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
firmonertinib BreakthroughOrphan | EGFR-mutant non-small cell lung cancer (NSCLC) | Phase 1b | 2025-11-10 | In the Phase 1b trial, firmonertinib demonstrated promising efficacy in EGFR PACC mutant NSCLC, leading to the advancement into pivotal Phase 3 trials, with specific results not detailed in the press release. Read More | ArriVent BioPharma Reports Third Quarter 2025 Financial Results Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received Read More | |
firmonertinib BreakthroughOrphan | EGFR-mutant non-small cell lung cancer (NSCLC) | Phase 1b | 2025-11-10 | In the Phase 1b trial, firmonertinib demonstrated promising efficacy in EGFR PACC mutant NSCLC, leading to the advancement into pivotal Phase 3 trials, with specific results not detailed in the press release. Read More | ArriVent BioPharma Reports Third Quarter 2025 Financial Results Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received Read More | |
firmonertinib BreakthroughOrphan | EGFR-mutant non-small cell lung cancer (NSCLC) | Phase 1b | 2025-11-10 | In the Phase 1b trial, firmonertinib demonstrated promising efficacy in EGFR PACC mutant NSCLC, leading to the advancement into pivotal Phase 3 trials, with specific results not detailed in the press release. Read More | ArriVent BioPharma Reports Third Quarter 2025 Financial Results Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVBP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVBP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVBPArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma reported its Q1 2026 financial results, highlighting significant advancements in its clinical pipeline. The company anticipates pivotal Phase 3 data for firmonertinib in mid-2026 and has received IND clearance for ARR-002, a dual-targeting ADC. Financially, ArriVent maintains a robust cash position to support operations through late 2027.
Read more →AVBPArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma has received FDA clearance for its investigational drug ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b. This ADC aims to treat ovarian and endometrial cancers, showing promising preclinical results in terms of efficacy and safety. A Phase 1 trial is expected to begin in the second half of 2026.
Read more →AVBPAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Aarvik Therapeutics will present at the AACR Annual Meeting 2026, showcasing its ADC capabilities. The company will feature two posters and an oral presentation, focusing on its MUTTA™ and AQUALINK™ platforms. These presentations aim to demonstrate advancements in cancer therapies, particularly for ovarian and endometrial cancers, through innovative dual-target ADCs.
Read more →AVBPArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
ArriVent BioPharma announced two poster presentations at the 2026 AACR Annual Meeting, focusing on firmonertinib, an EGFR inhibitor, and ARR-002, a dual-target ADC. Firmonertinib shows significant potential against EGFR mutations, while ARR-002 exhibits superior efficacy in ovarian cancer models. Both candidates are advancing towards clinical evaluation.
Read more →AVBPArriVent BioPharma Reports Full Year 2025 Financial Results Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Phase 3 first-line PACC
ArriVent BioPharma reported its financial results for the year ending December 31, 2025, highlighting significant progress in the development of firmonertinib for treating uncommon EGFR mutations in NSCLC. The CEO noted that firmonertinib is advancing towards potential registration, with pivotal trial data expected in mid-2026. The company's portfolio also includes an antibody-drug conjugate targeting gastrointestinal cancers, reflecting its commitment to addressing high unmet medical needs in oncology. The organization is well-positioned with a strong balance sheet and a cash runway expected to last into Q3 2027.
Read more →AVBPArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
ArriVent BioPharma has initiated the global pivotal Phase 3 ALPACCA trial, dosing the first patient with firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). This trial aims to evaluate firmonertinib against current treatment options, addressing a significant unmet need in this patient population. The study's endpoints include overall response rate and progression-free survival.
Read more →AVBPArriVent BioPharma Reports Third Quarter 2025 Financial Results Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received
ArriVent BioPharma reported strong financial results for Q3 2025, highlighting progress in its firmonertinib program for EGFR-mutant non-small cell lung cancer (NSCLC). The company is conducting pivotal Phase 3 trials for both PACC mutant and exon 20 insertion mutant NSCLC. Their lead candidate firmonertinib, recently granted FDA Breakthrough Therapy Designation, aims to fulfill significant unmet needs in these underserved populations. Additionally, the firm is advancing its antibody-drug conjugate (ADC) pipeline, projecting further developments toward clinical trials.
Read more →AVBPArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology sector. Rice's prior role at Autolus Therapeutics involved leading global commercialization strategies. His expertise is expected to strengthen ArriVent's commercial foundation as the company approaches the potential approval of firmonertinib for treating EGFR mutant non-small cell lung cancer.
Read more →AVBPArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
ArriVent BioPharma presented promising final analysis data from the Phase 1b FURTHER trial for firmonertinib, an oral EGFR inhibitor, at the 2025 World Conference on Lung Cancer. The study showed a prolonged progression-free survival of 16 months in patients with EGFR PACC mutations. The company plans to initiate a Phase 3 trial for these patients later this year.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2025 Financial Results
ArriVent BioPharma reported its financial results for Q2 2025, highlighting the progress of firmonertinib, which is advancing towards registration with promising interim data from the Phase 1b trial. The company plans to present final data at the World Conference on Lung Cancer and is set to enroll patients in a pivotal Phase 3 study. Additionally, the ADC pipeline is progressing, with the first patient dosed for ARR-217.
Read more →AVBPArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
ArriVent BioPharma has announced that topline data from its pivotal Phase 3 FURVENT study on firmonertinib for first-line NSCLC with EGFR exon20 insertion mutations is expected in early 2026. The study, which has completed enrollment, aims to evaluate progression-free survival compared to standard chemotherapy. Firmonertinib has also received FDA Breakthrough Therapy Designation for this indication.
Read more →AVBPArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma has announced the pricing of a public offering, raising approximately $75 million through the sale of common stock and pre-funded warrants. The offering is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, with a closing date expected around July 3, 2025. Proceeds will be used to further develop firmonertinib and other pipeline projects.
Read more →AVBPArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma, Inc. has announced its intention to conduct a public offering of $75 million in common stock and pre-funded warrants. The proceeds will be utilized to advance its lead therapeutic candidate, firmonertinib, amidst other pipeline initiatives. Major financial firms, including Goldman Sachs and Citigroup, are managing the offering, which is contingent on market conditions. This move reflects the company's strategy to enhance its capabilities in the biopharmaceutical sector.
Read more →AVBP▼ -9.6%on this news
Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study 16.0 months median progression
Arrivent BioPharma has announced positive interim results from its Phase 1b study of firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). The study reported a median progression-free survival of 16 months and notable central nervous system activity, with a significant proportion of patients achieving complete and overall responses. Based on these encouraging findings, Arrivent plans to advance firmonertinib into a global pivotal Phase 3 study, with patient enrollment expected to begin in the second half of 2025. The company aims to address unmet medical needs in this underserved patient population.
Read more →AVBP▼ -9.6%on this newsshared move
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
ArriVent BioPharma announced a virtual investor event to discuss the clinical program for firmonertinib, targeting EGFR PACC mutant non-small cell lung cancer (NSCLC). The event is scheduled for June 23, 2025. Firmonertinib has shown promise in treating various EGFR mutations and has received significant regulatory designations. The company aims to address the unmet needs of patients with uncommon mutations.
Read more →AVBPArriVent BioPharma Reports First Quarter 2025 Financial Results Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned up
ArriVent BioPharma reported its financial results for the first quarter of 2025, highlighting its progress in oncology, particularly with firmonertinib. The company has completed enrollment in a global pivotal Phase 3 study and anticipates presenting updated data regarding efficacy metrics later in the year. Despite a significant increase in net loss and operating expenses, the firm is preparing for potential near-term milestones with both firmonertinib and a newly acquired antibody drug conjugate, ARR-217. The financial outlook remains cautious due to inherent risks associated with forward-looking statements.
Read more →AVBPArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
ArriVent BioPharma announced the appointment of Dr. Merdad Parsey to its Board of Directors. Dr. Parsey, with decades of experience in leading clinical development, is expected to play a critical role as the company advances its lead candidate, firmonertinib, and its antibody drug conjugate pipeline. His background includes key positions at prominent biopharmaceutical companies and a strong academic foundation in immunology. The company aims to address significant unmet medical needs in cancer treatment with its differentiated therapeutic candidates.
Read more →AVBP▼ -6.7%on this news
ArriVent BioPharma Reports Full Year 2024 Financial Results First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations Global pivota
ArriVent BioPharma reported its full year 2024 financial results, highlighting substantial advancements in its clinical programs, particularly for firmonertinib, which shows promising efficacy against specific EGFR mutations in NSCLC. The company achieved target enrollment in a pivotal Phase 3 study and is planning to provide updates on future investigation plans. Additionally, ArriVent bolstered its ADC pipeline, demonstrating a commitment to addressing unmet medical needs in cancer therapy. The firm continues to progress toward significant clinical milestones in the upcoming year.
Read more →AVBPArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers Exclusive global license outside of Greater China for MRG007, a novel a
ArriVent BioPharma has entered an exclusive license agreement with Lepu Biopharma for MRG007, an antibody-drug conjugate targeted for gastrointestinal cancers. The deal grants ArriVent worldwide commercial rights outside Greater China and sets the first Investigational New Drug submission for MRG007 in the first half of 2025. This collaboration aims to advance the development of MRG007, which has already demonstrated strong potential in preclinical studies. The agreement further strengthens ArriVent's portfolio of next-generation antibody drug conjugates.
Read more →AVBP▼ -11.9%on this news
ArriVent BioPharma Reports Third Quarter 2024 Financial Results Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global
ArriVent BioPharma reported encouraging third quarter 2024 financial results, highlighting the robust activity of firmonertinib in treating non-small cell lung cancer (NSCLC) with EGFR PACC mutations. The company anticipates key clinical milestones, including updates on combination studies and pivotal trials expected in 2025. With $282.9 million in cash, ArriVent is well-funded to advance its lead candidate, firmonertinib, noted for its high efficacy in hard-to-treat patient populations. These results position ArriVent favorably in the emerging market for targeted cancer therapies.
Read more →AVBPArrivent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer 81.8% ORR by B
ArriVent BioPharma announced positive interim results from their Phase 1b study evaluating firmonertinib for treating first-line EGFR PACC mutant non-small cell lung cancer. The drug achieved an 81.8% overall response rate and 63.6% confirmed ORR, showcasing its potential efficacy in this patient population. High CNS response rates were observed, indicating firmonertinib's promise as a treatment option for patients with CNS metastases. Results and future plans for development will be discussed in a webinar on September 9, 2024.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2024 Financial Results Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented
ArriVent BioPharma has reported its second quarter 2024 financial results, highlighting significant advances in its oncology pipeline. A major focus is the upcoming presentation of proof-of-concept data for firmonertinib, which is intended for patients with EGFR PACC mutant non-small cell lung cancer. Additionally, the company recently entered into a collaboration agreement with Alphamab to expand its antibody drug conjugate portfolio. The firm is also actively advancing studies for firmonertinib across multiple indications, aided by a strong financial position evidenced by increased cash reserves.
Read more →AVBPArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent BioPharma, Inc. announced it will present interim randomized Phase 1b data for Firmonertinib as a treatment for non-small cell lung cancer with EGFR PACC mutations at the 2024 World Conference on Lung Cancer. The presentation is scheduled for September 9, 2024, and will be part of a Presidential Symposium session. Firmonertinib is notable for being the first small-molecule EGFR tyrosine kinase inhibitor specifically targeting this mutation. The drug has received significant designations from the FDA, highlighting its potential in addressing unmet medical needs in NSCLC.
Read more →AVBPArriVent Appoints Kristine Peterson to its Board of Directors NEWTON SQUARE, PA - April 22 , 2024 - ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative bioph
ArriVent BioPharma, Inc. has announced the appointment of Kristine Peterson to its Board of Directors. With over 30 years of experience in the biopharmaceutical sector, Peterson has previously held leadership roles at notable companies including Immunocore and Johnson & Johnson. Her involvement is expected to provide valuable insights as ArriVent seeks to further develop its lead candidate, firmonertinib, aimed at treating non-small cell lung cancer. The company is focused on addressing unmet medical needs in cancer treatment and advancing a pipeline of therapeutics.
Read more →AVBPArriVent Announces a Multi-Target ADC Collaboration with Alphamab Collaboration will leverage Alphamab's antibody drug conjugate ("ADC") research and discovery platform and ArriVent's global development and commercializa
ArriVent BioPharma has announced a collaboration with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody drug conjugates (ADCs) aimed at treating cancers. Under the agreement, ArriVent will leverage Alphamab's proprietary linker-payload platform and glycan-conjugation technology, with the potential for payments totaling up to $615.5 million. This partnership aims to address unmet medical needs in oncology while expanding both companies' product pipelines. Alphamab retains rights for ADC development in Greater China, while ArriVent focuses on global commercialization.
Read more →AVBPArriVent Appoints John Hohneker, M.D., to its Board of Directors
ArriVent BioPharma, Inc. announced the appointment of Dr. John Hohneker to its Board of Directors. Dr. Hohneker brings over 30 years of biopharmaceutical experience, which includes leadership roles at multiple companies. His expertise is expected to bolster the development of ArriVent's pipeline, particularly the lead candidate firmonertinib. The company is working to address unmet needs in cancer treatment, aiming for successful outcomes in ongoing clinical trials.
Read more →AVBPArriVent BioPharma Reports First Quarter 2024 Financial Results Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research ("AACR") Annual Meeting Dosed first p
ArriVent BioPharma has reported its financial results for Q1 2024, demonstrating significant progress in its clinical studies. The company completed enrollment for its Phase 1b trial focusing on NSCLC patients and initiated a combination study involving firmonertinib. Recent data presented at the AACR Annual Meeting showcased firmonertinib's effectiveness against a variety of EGFR mutations. Additionally, the company aims to leverage its strong pipeline to address existing gaps in cancer therapeutics.
Read more →AVBPArriVent Appoints Kristine Peterson to its Board of Directors
ArriVent BioPharma has appointed Kristine Peterson to its Board of Directors, bringing over 30 years of biopharmaceutical leadership experience. Peterson has previously held significant roles in companies such as Immunocore, Enanta Pharmaceuticals, and Valeritas, indicating her strong background in drug development and commercialization. The appointment comes at a critical time for ArriVent as it advances its lead candidate firmonertinib for non-small cell lung cancer indications. Peterson expressed excitement about working with the team to address the needs of cancer patients.
Read more →AVBPKristine Peterson to its Board of Directors
ArriVent BioPharma announced the appointment of Kristine Peterson to its Board of Directors, bringing over 30 years of biopharmaceutical leadership experience. Peterson, who has served on the boards of notable public companies and has extensive experience in drug development and commercialization, is expected to provide valuable insights to support the company's mission. Her appointment is deemed timely as ArriVent advances the development of its lead candidate, firmonertinib, aimed at addressing unmet needs in non-small cell lung cancer.
Read more →AVBPArriVent Biopharma Reports Full Year 2023 Financial Results Company progresses the development of furmonertinib with a data readout planned for 2024 Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food
ArriVent Biopharma has announced its financial results for 2023, highlighting a significant loss while demonstrating progress with its lead drug furmonertinib. The drug has been granted Breakthrough Therapy Designation by the FDA, which could expedite its development. The company has a strong cash position, allowing for operations through 2026, and plans to advance its ongoing clinical trials for furmonertinib. However, the increase in operating expenses and substantial net losses raise concerns about future profitability.
Read more →AVBPArriVent Announces Pricing of Upsized Initial Public Offering
ArriVent BioPharma has announced the pricing of its upsized initial public offering of 9.72 million shares at $18.00 each, aiming to raise around $175 million before fees. The shares will trade on the Nasdaq under the ticker AVBP starting January 26, 2024, with the offering expected to close by January 30, 2024. This capital will support ArriVent's focus on developing novel cancer therapeutics, including its lead candidate furmonertinib. The underwriters have also been granted an option to purchase additional shares.
Read more →AVBPArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer
ArriVent Biopharma, Inc. has announced the appointment of Winston Kung as Chief Financial Officer and Treasurer. Mr. Kung brings over 20 years of leadership experience in life sciences, most recently serving at PMV Pharmaceuticals. His expertise is expected to be pivotal as ArriVent advances its furmonertinib program, aiming to address unmet medical needs in cancer treatment. Kung expressed his commitment to leveraging his experience to help reach global patient populations in need of transformative therapies.
Read more →AVBPArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
ArriVent Biopharma has received FDA Breakthrough Therapy designation for its drug furmonertinib, which is intended for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This designation is supported by promising interim results from the FAVOUR clinical trial, indicating significant anti-tumor activity and a favorable safety profile. The company plans to further its development efforts through the ongoing global Phase 3 FURVENT trial, which is currently enrolling patients. This advancement underscores the critical need for effective therapeutic options for patients with this type of lung cancer.
Read more →AVBPArriVent Appoints Chris Nolet to its Board of Directors
ArriVent Biopharma has announced the appointment of Chris Nolet to its Board of Directors, bolstering its leadership team as it advances the global development of furmonertinib for non-small cell lung cancer. Nolet, who has extensive experience in the life sciences industry, will provide valuable insights into financial markets and capital structuring. His role is expected to be particularly impactful as ArriVent progresses with its ongoing Phase 3 study and continues to develop a robust pipeline. The appointment is seen as opportune for enhancing the company's strategic direction.
Read more →AVBPArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
ArriVent Biopharma has successfully closed a $155 million oversubscribed Series B financing, aimed at supporting pivotal Phase 3 studies of its lead candidate furmonertinib, a mutant-specific EGFR kinase inhibitor. The financing round included participation from both new and existing investors, establishing a robust financial foundation for future pipeline expansion. With this financing, ArriVent has now raised over $300 million in total to advance its oncology therapeutics and enhance global access to innovative medications.
Read more →AVBPArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations
Furmonertinib granted Fast Track Designation in this indication by the U.S. Food and Drug Administration NEWTOWN SQUARE, Pa., July 05, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., dedicated to accelerating the global development of innovative biopharmaceutical therapeutics
Read more →AVBPArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment of Bahija Jallal, Ph.D. to its Board of Directors. Dr. Jall
Read more →AVBPArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset
Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development Company enters first licensing agreement with Allist Pharma, granting ArriVent ex-China development, manufacturing and commercialization rights to novel EGFR TKI NEWTOWN SQU
Read more →Competitive Position
How AVBP ranks across every disease it competes inCompetitive Position is a premium feature
See how AVBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial